Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma - PubMed
5 hours ago
- #linvoseltamab
- #clinical trial
- #multiple myeloma
- Linvoseltamab, a BCMA×CD3 bispecific antibody, was studied in triple-class exposed or refractory relapsed/refractory multiple myeloma patients.
- A Phase 2 cohort (105 patients) receiving linvoseltamab 200 mg was compared to an external control arm of 203 real-world standard-of-care patients.
- Linvoseltamab showed significantly higher objective response rates and longer progression-free survival compared to real-world standard-of-care.
- The treatment also resulted in longer time to next treatment and improved overall survival in this patient population.
- These results suggest linvoseltamab as an effective therapeutic option for advanced, heavily pretreated multiple myeloma.